Conversion of Astrocyte Cell Lines to Oligodendrocyte Progenitor Cells Using Small Molecules and Transplantation to Animal Model of Multiple Sclerosis
Journal of Molecular Neuroscience · 2024
DOI: 10.1007/s12031-024-02206-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Neuroscience, 2024. Verfasst von Mohsen Sharifi-Kelishadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Multiple Sclerosis, Oligodendrocyte Precursor Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Faculty of Medical Sciences, Tarbiat Modares University, Royan Institute.
Abstract (Originalsprache)
Astrocytes, the most prevalent cells in the central nervous system (CNS), can be transformed into neurons and oligodendrocyte progenitor cells (OPCs) using specific transcription factors and some chemicals. In this study, we present a cocktail of small molecules that target different signaling pathways to promote astrocyte conversion to OPCs. Astrocytes were transferred to an OPC medium and exposed for five days to a small molecule cocktail containing CHIR99021, Forskolin, Repsox, LDN, VPA and Thiazovivin before being preserved in the OPC medium for an additional 10 days. Once reaching the OPC morphology, induced cells underwent immunocytofluorescence evaluation for OPC markers while checked for lacking the astrocyte markers. To test the in vivo differentiation capabilities, induced OPCs were transplanted into demyelinated mice brains treated with cuprizone over 12 weeks. Two distinct lines of astrocytes demonstrated the potential of conversion to OPCs using this small molecule cocktail as verified by morphological changes and the expression of PDGFR and O4 markers as well as the terminal differentiation to oligodendrocytes expressing MBP. Following transplantation into demyelinated mice brains, induced OPCs effectively differentiated into mature oligodendrocytes. The generation of OPCs from astrocytes via a small molecule cocktail may provide a new avenue for producing required progenitors necessary for myelin repair in diseases characterized by the loss of myelin such as multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- Institute for Brain and Cognition, Tarbiat Modares University, Tehran, Iran.
- Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. mjavan@modares.ac.ir.
- Institute for Brain and Cognition, Tarbiat Modares University, Tehran, Iran. mjavan@modares.ac.ir.
- Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. mjavan@modares.ac.ir.
ORCID-Profile: Yaghoub Fathollahi, Mohammad Javan
Förderung
- Faculty of Medical Sciences, Tarbiat Modares University
- Royan Institute
Zitieren
APA
Sharifi-Kelishadi, M., Zare, L., Fathollahi, Y., & Javan, M. (2024). Conversion of Astrocyte Cell Lines to Oligodendrocyte Progenitor Cells Using Small Molecules and Transplantation to Animal Model of Multiple Sclerosis. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-024-02206-6
Vancouver
Sharifi-Kelishadi M, Zare L, Fathollahi Y, Javan M. Conversion of Astrocyte Cell Lines to Oligodendrocyte Progenitor Cells Using Small Molecules and Transplantation to Animal Model of Multiple Sclerosis. Journal of Molecular Neuroscience. 2024. doi:10.1007/s12031-024-02206-6
BibTeX
@article{SharifiKelishadi2024,
author = {Sharifi-Kelishadi, Mohsen and Zare, Leila and Fathollahi, Yaghoub and Javan, Mohammad},
title = {Conversion of Astrocyte Cell Lines to Oligodendrocyte Progenitor Cells Using Small Molecules and Transplantation to Animal Model of Multiple Sclerosis},
journal = {Journal of Molecular Neuroscience},
year = {2024},
doi = {10.1007/s12031-024-02206-6}
}
EUVIMED